Combined molecular and clinical diagnosis: ≥2 tumors with loss of heterozygosity on the long arm of chromosome 22 and 2 different somatic NF2 mutations and ≥2pathologically confirmed SCHs or meningiomas or germline SMARCB1 or LZTR1 pathogenic mutation and one pathologically confirmed SCH or meningioma. The gene discussed is SMARCB1; the disease is meningioma.